Phase II study of MTX-HSA in combination with cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma.

Purpose: To assess the efficacy, tolerability and safety of MTX-HSA (methotrexate (MTX) covalently linked to human serum albumin (HSA)) combined with cisplatin as first line therapy for advanced bladder cancer.

Methods: Patients (pat) were treated with a loading dose of 110 mg/m(2) of MTX-HSA followed by a weekly dose of 40 mg/m(2) starting on day 8. Cisplatin was given on day 2 of each 28 day cycle at a dose of 75 mg/m(2).

[Review and results of our first ureteroscopy experience at the Klaipeda Hospital].

Objective: To estimate an experience of our first ureteroscopic procedures.

Material And Methods: The data of 65 patients, who underwent ureteroscopy in Klaipeda Hospital during period 2000 August - 2002 February were analyzed. The indications were: obstructive ureteral stones after not successful extracorporeal lithotripsy, rigid ureteral stones, radionegative ureteral stones and ureteral strictures.

[Results of the treatment of kidney and ureteral stones by the method of extracorpored shock wave lithotripsy at the Klaipeda Hospital].

review the cases, which are cured by extracorpored shock wave lithotripsy using the device of third generation "Lithostar Multiline" (Germany). There are data of 603 patients treated by extracorpored shock wave lithotripsy. Almost a thousand (979) renal stones' fragmentations were performed for 271 (45%) patients.